CJC-1295 No DAC 5mg + Ipamorelin 5mg + BPC-157 15mg: Product & Research Information

Product Overview

CJC-1295 No DAC 5mg + Ipamorelin 5mg + BPC-157 15mg is a three-peptide combination presented for research-oriented reference. According to the listed formulation, each vial contains 5 mg of CJC-1295 No DAC, 5 mg of Ipamorelin, and 15 mg of BPC-157, for a stated total peptide content of 25 mg. These labeled quantities do not independently confirm the product’s identity, purity, or quality.

The three peptides are associated with different areas of scientific investigation. CJC-1295 No DAC is discussed in relation to growth hormone-releasing hormone (GHRH) signaling. Ipamorelin is studied for its interaction with the ghrelin receptor, also known as GHS-R1a. BPC-157 is an experimental peptide investigated primarily in preclinical research involving biological processes and tissue responses.

Understanding the Three Peptides

CJC-1295 No DAC — 5mg

CJC-1295 No DAC is commonly described as a modified GHRH-related peptide without the Drug Affinity Complex (DAC) modification associated with longer-acting CJC-1295 formulations. Commercial naming conventions can vary, so the precise molecular identity should be confirmed through appropriate product documentation.

Ipamorelin — 5mg

Ipamorelin is a peptide studied for its activity at the ghrelin receptor (GHS-R1a), a signaling pathway associated with growth hormone secretion. Research involving an individual ingredient does not establish the safety, efficacy, or performance of a combination containing that ingredient.

BPC-157 — 15mg

BPC-157 is an experimental peptide investigated primarily in preclinical studies. Scientific interest in tissue-related biological processes does not establish that BPC-157 heals injuries, repairs human tissue, or provides proven recovery benefits in people. Its safety and clinical effectiveness remain insufficiently established.

Three-Peptide Research Context

This formulation combines peptides associated with different biological pathways. However, the combination’s composition alone does not demonstrate synergistic effects or establish that the three compounds are safe or effective when used together. Findings from laboratory or animal studies should not be presented as proven clinical benefits, and evidence relating to one peptide cannot be assumed to apply to the complete blend.

Product Identification and Quality Documentation

For accurate product identification, review the supplied label and any available batch-specific documentation. Where a certificate of analysis (COA) is available, relevant details may include the batch or lot number, analytical methods, identity testing, purity results, and other applicable quality measures.

A COA should be described accurately and should not be treated as proof of clinical efficacy, human safety, or regulatory approval. Product-specific quality claims should only be published when supported by appropriate documentation.

Safety and Regulatory Considerations

CJC-1295, ipamorelin, and BPC-157 have important safety-data limitations. The U.S. Food and Drug Administration has identified potential concerns associated with certain compounded products containing these substances, including peptide-related impurities and possible immunogenicity. FDA materials also describe limited safety information for BPC-157 and limited clinical data for CJC-1295.

These concerns mean that this formulation should not be marketed as an established treatment, a proven injury-recovery solution, or a clinically validated hormone-related product. The safety and effectiveness of this exact three-peptide combination have not been established by the product description.

This information is provided for educational and research-reference purposes only. It is not medical advice or a recommendation for human use. Regulatory requirements vary by jurisdiction; applicable rules should be reviewed before purchasing, handling, distributing, or using peptide products.

Peptika product information: Refer to the current product label and available batch-specific documentation for details about the item supplied.

Peptide quality documentation

CJC-1295 NO-DAC 5mg + Ipa 5mg + BPC-157 15mg